Genetic and pharmacologic targeting of the PTEN/PI3K/AKT/mTOR signaling pathway was used as a potential therapeutic strategy in the peripheral neuropathies Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) and Charcot Marie Tooth disease type 1A (CMT1A). The gene discussed is MTOR; the disease is hereditary neuropathy with liability to pressure palsies.